Company
(Symbol)^#
(M)

Type Of
Financing

Number Of
Shares, Units
Or Warrants

Amount
Raised
(M)

Investors; Placement Agents; Details
(Date)^@

Advancis
Pharmaceutical
Corp. (AVNC)

Private placement of units

U comprised of 10.2S and W for 7.6S

$24

Advancis raised the money by placing units comprised of 10.2M common shares and warrants for another 7.6M shares, priced at $2.35375 apiece; Pacific Growth Equities LLC acted as the placement agent (4/10)

Alteon Inc.
(AMEX:ALT)

Private placement of Series B preferred stock and warrants

N/A

$25

Alteon raised $25M in its placement; Rodman & Renshaw served as placement agent (4/9)

Ambrilia
Biopharma
Inc. (Canada;
TSX:AMB)

Private placement of common stock

2.2S

$5.4

Ambrilia raised $5.4M through the sale of 2.2M shares at $2.42 each (4/19)

AVAX
Technologies
Inc. (OTC BB:
AVXT)

Private placement of common stock

80S and W for 80S

$10

AVAX raised $10M through the sale of 80M shares to certain accredited and institutional investors, who also will receive warrants to purchase an additional 80M shares (4/16)

BCY
LifeSciences
Inc. (Canada;
CDNX:BCY)

Private placement of units

20U

C$1($0.872)

BCY is raising $872,600 through the sale of 20M units at 4 cents per unit; each unit consists of a common share and a warrant for the purchase of one additional common share at 9 cents within two years (4/12)

Bioenvision
Inc. (BIVN)

Private placement of common stock

8S

$30

Bioenvision raised $30M offering the shares at $3.75 each; JP Morgan Securities is exclusive placement agent (4/2)

BioMarin
Pharmaceutical
Inc. (BMRN)

Placement of senior subordinated convertible notes

N/A

$324.9

BioMarin raised $324.9M in a public offering of 1.87% senior subordinated convertible notes due 2017; the underwriter, Merrill Lynch & Co., exercised an option to purchase $42.375M in additional notes to cover overallotments (4/18)

Carrington
Laboratories
Inc. (CARN)

Private placement of convertible debentures and common stock warrants

2.99W

$8

Carrington raised $8M through the placement being done in two closings; the financing includes the issuance of about 2.99M seven-year warrants exercisable at $2.01 (4/26)

Cell Genesys
Inc. (CEGE)

Private placement of common stock and warrants

10.8S and 2.2W

$60

Cell Genesys raised $60M through the placement led by Credit Suisse Securities LLC; Needham & Co. LLC, Cantor Fitzgerald & Co. and Canaccord Adams Inc. served as co-placement agents (4/11)

Cell
Therapeutics
Inc. (CTIC)

Private placement of stock and warrants

N/A

$37.2

Cell Therapeutics offered $37.2M of 3% convertible stock and warrants, selling Series B preferred stock at $1,000 per share; they will be convertible at $1.68 per share, or $6.73 per share after a one-for-four reverse stock split effective April 15; purchasers also are receiving warrants to buy common stock in an amount equal to 50% of their total investment amount; Rodman & Renshaw acted as exclusive placement agent (4/12)

Cel-Sci Corp.
(AMEX:CVM)

Private placement of common stock and warrants

20S and 20W

$15

Cel-Sci raised $15M in the placement of 20M shares and 10M warrants exercisable at 75 cents per share, and another 10M exercisable at $2 per share (4/18)

ChemGenex
Pharmaceuticals
Ltd. (Australia;
CXSP)

Private placement of common stock and options

16.9S

A$10.5 (US$8.53)

The money was raised through a rights issue of 16.9M shares and associated options; Alta Partners and GBS Venture Partners participated (4/3)

Clinuvel
Pharmaceuticals
Ltd. (Australia;
ASX:CUV)

Private placement of common stock

24.3S

A$26 ($21.5)

Clinuvel raised $21.5M in a placement with Australian and European institutions (4/26)

Corcept
Therapeutics
Inc. (CORT)

Private placement of common stock

9S

$9

Corcept offered the shares at $1 each; Paperboy Ventures LLC led the financing, which included participation from Sutter Hill Ventures, Alta Partners LLP, members of the Corcept board, Black Point Group LLP and certain individuals (4/2)

CytRx Corp.
(CYTR)

Private placement of common stock

8.6S

$37

CytRx raised $37M through the placement (4/18)

Depomed Inc. (DEPO)

Private placement of common stock

5.3S

$20

Depomed raised $20M through the sale of 5.3M shares to a pair of institutional investors at $3.77 per share (4/23)

Discovery
Laboratories
Inc. (DSCO)

Private placement of common stock

14.05S

$30.2

Discovery offered the shares to institutional investors at $2.15 apiece (4/3)

Elite
Pharmaceuticals
Inc. (AMEX:ELI)

Private placement of preferred stock

0.015S

$15

Elite raised $15M issuing 15,000 shares of Series C stock at $1,000 per share; each share is convertible at $2.32 into 431.03 shares for an aggregate of 6.5M shares; Oppenheimer & Co. Inc. acted as the lead placement agent (4/25)

EpiCept Corp.
(EPCT)

Private placement of common stock and warrants

6.9S and W for 3.4S

$10

EpiCept raised $10M, placing 6.9M shares at $1.46 each, as well as warrants for an additional 3.4M shares priced at $1.47 each (4/9)

Halozyme
Therapeutics
Inc. (AMEX:HTI)

Private placement of common stock

3.5S

$32.1

Halozyme raised $32.1M through an investment from its largest shareholders, New River Management V LP (4/24)

Innovive
Pharmaceuticals
Inc. (OTC BB:IVPH)

Private placement of common stock

ND

$15

Innovive raised $15M with Paramount BioCapital acting as placement agent (4/25)

Manhattan
Pharmaceuticals
Inc.
(AMEX:MHA)

Private placement of common stock

10.2S

$8.6

Manhattan offered the shares at 84 cents each; investors also got five-year warrants to buy about 3.6M shares at $1 per share; Paramount Capital Inc. was placement agent (4/2)

Microbix
Biosystems
Inc. (Canada;
TSX:MBX)

Private placement of units

1.5U

$1.05

Microbix raised $1.05M offering 1.5M units at 70 cents apiece; each unit consists of one common share and one-half of a common share purchase warrant; each whole warrant entitles the holder to subscribe for one common share priced at 90 cents for a period of 18 months (4/20)

Neurobiological
Technologies
Inc. (NTII)

Private placement of units

U for 3.04S

$7

NTI is selling units at $2.30 each; institutional investors also will get five-year warrants to buy another 3.04M shares at $2.40 each; Rodman & Renshaw LLC and Dawson James Securities are placement agents (4/2)

Novelos
Therapeutics
Inc. (OTC BB:
NVLT)

Private placement of convertible preferred stock and warrants

0.0015S and W for 7.5S

$15

Novelos raised $15M issuing 1,500 shares of Series B convertible preferred stock valued at $10,000 per share, and warrants to buy a total of 7.5 million shares of common stock; investors were Xmark Opportunity Funds, OrbiMed Advisors and other selected institutional investors; Rodman & Renshaw served as placement agent, and Emerging Growth Equities Ltd. acted as the sub-placement agent (4/13)

Oscient
Pharmaceuticals
Corp. (OSCI)

Private placement of convertible notes

N/A

$60

Oscient raised $60M through the placement; Piper Jaffray & Co. is the placement agent (4/26)

Pluristem Life
Systems Inc.
(OTC BB:PLRS)

Warrant exercise

15W

$1.1

Pluristem raised $1.1M through the exercise of about 15M warrants at 7.5 cents each (4/4)

Redpoint
Bio Corp.
(OTC BB:RBCR)

Private placement of stock and warrants

N/A

$13

Redpoint raised another $13M as part of a financing begun in March, bringing the total raised to $33M (4/9)

ReGen
Biologics Inc.
(OTC BB:RGBI)

Private placement of Series D preferred stock and warrants

64.3S and w for 19.3S

$2.7

ReGen completed an additional $2.7M placement, which, when combined with placements in December 2006 and March 2007, brings the company's total fund raising to about $12.7M; the placement was led by Ivy Capital Partners LLC (4/6)

Sequenom
Inc. (SQNM)

Private placement of common stock

6.7S

$20

Sequenom raised $20M in a placement with institutional investors; Lehman Brothers Inc. was the lead placement agent, with Rodman & Renshaw LLC acting as co-placement agent (4/30)

Titan
Pharmaceuticals
Inc. (AMEX:TTP)

Private placement of common stock

5.4S

$11

Titan raised $11M through the placement of 5.4M shares at $2.02 each; Rodman & Renshaw LLC acted as the placement agent (4/25)

Viragen Inc.
(AMEX:VRA)

Private placement of units

0.03U

$3

Viragen raised $3M through the private sale of 30,000 units at $100 per unit to RAB Capital plc; each unit consists of one share of Series K cumulative convertible preferred stock and five-year warrants to purchase 500 shares of common stock at 10 cents per share (4/16)

Vyteris
Holdings Inc.
(OTC BB:VYHN)

Private placement

ND

$20.1

The transaction included $20.1M in cash, as well as another $3M in non-cash debt conversion (4/27)